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Abstract In recent years, it has become clear that the
neuronal nicotinic acetylcholine receptor (nAChR) is a
valid target in the treatment of a variety of diseases,
including Alzheimer’s disease, anxiety, and nicotine addic-
tion. As with most membrane proteins, information on the
three-dimensional (3D) structure of nAChR is limited to
data from electron microscopy, at a resolution that makes
the application of structure-based design approaches to
develop specific ligands difficult. Based on a high-
resolution crystal structure of AChBP, homology models
of the extracellular domain of the neuronal rat and human
nAChR subtypes α4β2 and α7 (the subtypes most
abundant in brain) were built, and their stability assessed
with molecular dynamics (MD). All models built showed
conformational stability over time, confirming the quality
of the starting 3D model. Lipophilicity and electrostatic
potential studies performed on the rat and human α4β2 and
α7 nicotinic models were compared to AChBP, revealing
the importance of the hydrophobic aromatic pocket and the
critical role of the α-subunit Trp—the homolog of AChBP-
Trp 143—for ligand binding. The models presented provide
a valuable framework for the structure-based design of
specific α4β2 nAChR subtype ligands aimed at improving
therapeutic and diagnostic applications.
Keywords Nicotinic acetylcholine receptor . Homology
modeling .Molecular dynamics . Hydrophobic and
electrophilic potentials . Subtype selectivity
Introduction
Ion channels are membrane proteins with an important
physiological and pharmacological role. The nicotinic
acetylcholine receptor (nAChR), a member of the Cys-loop
superfamily, is a ligand-gated ion channel located mostly in
the central and peripheral nervous system and neuromus-
cular junctions. In particular, neuronal nAChRs are present
in presynaptic regions to mediate acetylcholine neurotrans-
mission, and in the postsynaptic membrane to propagate the
nerve pulse, via acetycholine, through the neurons [1]. The
nAChR is composed of five subunits, which form a cation-
permeable pore built up of homopentamers or heteropen-
tamers. The binding sites are located at the interface
between the two extracellular subunits, and the number of
binding sites differs from subtype to subtype [2]. Thus,
different nAChR subtypes exist according to the type of α
and β-subunit composition. Opening of the channel can be
caused by agonists other than acetylcholine, like nicotine or
epibatidine [3], or by synthetic compounds [4]. Reconsti-
tution experiments performed in host systems such as
Xenopus laevis oocytes, and/or transfection in cell lines in
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combination with site-directed mutagenesis and single-
channel studies have been performed. The results of
reconstitution experiments have demonstrated that the
pentameric assemblies (α4)2(β2)3 and (α7)5 are the
subtype most abundant in the brain [5]. In addition,
the identification of many neuronal nAChR genes has
provided new insights into the mechanisms of neurotrans-
mission that correlate neurological diseases and nAChRs
[6]. In the last few years, neuronal nAChRs have become
an important drug target for a variety of diseases, including
Alzheimer’s disease [4].
Considerable effort has been made to investigate and
understand the structure of nAChRs, especially in the
binding site region. Due to problems with crystallization,
as is the case for most membrane proteins, the only
available three-dimensional (3D) structural information for
nAChRs involving both the extracellular ligand binding
domain (LBD) and the transmembrane domain (TMD) is
some low-resolution electron microscopy data from the
electric organ of the Torpedo ray [7, 8].
High-resolution crystallographic structures of the
homopentameric acetylcholine-binding protein (AChBP)
isolated from the freshwater snail Lymnaea stagnalis,
have revealed important information regarding activated
and desensitized nAChR-LBD [9–13]. This protein is
produced and stored in glia cells and released into the
synaptic cleft in an acetylcholine-dependent manner to
modulate neurotransmission. AChBP binds nAChR ago-
nists such as acetylcholine, nicotine and the competitive
antagonist α-bungarotoxin, and exhibits significant se-
quence homology with the extracellular part of nAChR
subunits (26% identity with subtype α7) [14]. Moreover,
AChBP exhibits pharmacological properties and ligand
affinities similar to those of the α7 homopentamer,
suggesting 3D structural similarities [15–17]. Therefore,
AChBP is a suitable template 3D-structure for the N-
terminal domain of nAChR α and β subunits.
In recent years, interesting structural investigations into
human nAChR subtype α7 showed, through molecular
dynamics (MD), important 3D-correlations during the
opening and closing of the ion channel between the
extracellular LBD and the TMD of the membrane protein
[18–22]. Recently, the role of water in the AChBP binding
pocket has also been taken into consideration [23].
In the present work, homology models of the
extracellular domain of neuronal rat and human nAChR
subtypes (α4)2(β2)3 and (α7)5 were built, their stability
assessed using MD, and the binding sites analyzed and
compared regarding lipophilicity and electrostatic poten-
tial. The present models provide a valuable framework for
the structure-based design of specific α4β2 nAChR
subtype ligands for future therapeutic and diagnostic
applications.
Methods
Sequence alignment and homology modeling
Multiple sequence alignment (the alignment of three or
more biological sequences of proteins sharing a common
evolutionary origin) between AChBP and the amino-
terminal extracellular domain of rat and human α7, and
rat and human α4 and β2 nAChR subunits was performed
using the Program DCA (Divide-and-Conquer Multiple
Sequence Alignment) of the Technical Faculty of the
University of Bielefeld (Germany) [24]. Homology model-
ing is a method for constructing an atomic-resolution 3D
model of a protein starting from its amino acid sequence
and using as a 3D-target another protein sharing a
detectable level of sequence similarity. The 3D-prediction
of the amino-terminal extracellular domain of human α7,
rat α7, human α4 and human β2 nAChR subunits was
performed with the program SwissModel [25–27] using the
First Approach Mode with user-defined 3D-templates
including energy minimization performed with the program
Gromos 96 [28].
For the amino-terminal extracellular domain of human
α7, rat α7, human α4, and human β2 subunits, the 3D-
templates used were the AChBP monomer [Pdb code=1i9b,
9], the amino-terminal extracellular domain of chick α7,
and rat α4 and β2 subunits [29], respectively. The 3D-
templates rat α4β2 and chick α7 pentamers were retrieved
from the Ligand-Gated Ion Channel database of the Pasteur
Institute, France [29].
The 3D models of the pentamer of neuronal rat and
human (α4)2(β2)3, rat (α7)5 and human (α7)5 nAChR
subtypes were assembled and manually refined, to correct
non-allowed geometrical parameters, with the software
SYBYL 6.8 (Tripos, St. Louis, MO). All assessment of
the geometry of the model was performed using the
program PROCHECK [30].
Energy minimization and molecular dynamics
Preparation of the AChBP dimer with acetylcholine in the
binding cavity took into account the 3D orientation of N-2-
hydroxyethylpiperazine-N′-2-ethane-sulfonate (HEPES).
Each binding site of the AChBP pentamer contains a
molecule of HEPES coming from the crystallization
procedure. Similar to known nicotinic ligands, this buffer
molecule has a positively charged nitrogen that stacks onto
Trp 143, making the very important cation-π interactions
essential for the binding of ligands to nicotinic receptors
[31, 32]. Acetylcholine was then inserted into the AChBP
binding site by matching the positively quaternary nitrogen
with the nitrogen of HEPES involved in the cation-π
interaction as shown in Fig. 1. Acetylcholine was param-
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eterized using the program ANTECHAMBER. The topol-
ogy and starting coordinates of the AChBP dimer with
acetylcholine in the binding cavity were prepared using
LEAP. The same procedure was used to generate 3D
models of the pentamer of neuronal rat and human
(α4)2(β2)3, rat (α7)5 and human (α7)5 nAChR subtypes
and the AChBP pentamer.
All pentamers were immersed in a box of water
molecules and Na+ counterions were added to the solvent
bulk of the protein/water complexes to maintain neutrality
of the system using program AMBER6 [33].
Periodic boundary conditions were applied. The Amber
force field [34] all atom parameters (parm94) were used for
the protein and Na+ ions. The minimization protocol
consisted of 1,000 cycles of steepest descent followed by
conjugate gradient method until the root-mean square
deviation (RMSD) of the Cartesian elements of the gradient
reached a value smaller than 0.15 Å.
The dynamic protocol consisted of three steps: MD1,
MD2 and MD3. The initial temperatures for MD1, MD2
and MD3 were set at 0, 150, 300°K, respectively, while the
targeted temperature during the run was 300°K. The
Berendsen’s coupling algorithm [35] was applied to keep
the temperature constant. The time step for all three
dynamic procedures was 0.002 ps. For minimization and
MD, the primary cutoff distance for non bonded interaction
was set at 9 Å.
Regarding the MD protocol used, the first step (MD1)
aimed for the equilibration of water molecules and ions of
the water-boxed and charge-neutralized model. An initial
velocity was given to the system and trajectories were then
allowed to evolve in time according to Newtonian laws,
keeping the model protein fixed. The number of dynamics
steps was 7,500, corresponding to 15 ps.
Fifteen picoseconds of constant volume dynamic (MD2)
was performed on the whole system to adjust the density to a
value of 1 atm. In the third step, a 500 ps constant pressure
dynamic (MD3) of 1 atm was applied without any constraint
to finally assess the stability of the models over time. The
energy minimization, MD and corresponding analysis were
performed using program AMBER6 [33]. All geometry
quality assessment of the models, at different time points,
was made using the program PROCHECK [30].
Lipophilicity and electrostatic potential studies
The lipophilicity and electrostatic potential surfaces of
AChBP and the rat and human nicotinic models were
examined using the program MOLCAD implemented in
SYBYL 6.8 [36].
Results and discussion
Sequence alignment and homology modeling
Sequence alignment revealed the identities and homology
between AChBP and the amino-terminal extracellular
domain of nAChR subtypes human α7, the amino-terminal
extracellular domain of chick α7 and rat α7, and the amino-
terminal extracellular domains of rat α4, rat β2 and human
α4, human β2; percentage identities are shown in Table 1.
There is high homology between the same nicotinic
Table 1 Percentage of sequence identities between acetylcholine-
binding protein (AChBP) and the amino-terminal extracellular domain
of nicotinic acetylcholine receptor (nAChR) subtypes human α7, the
amino-terminal extracellular domain of chick α7 and rat α7, and the
amino-terminal extracellular domains of rat α4, rat β2 and human α4,
human β2 computed with the LALIGN program [40]
Template
AChBP α 7c α 4r β 2r
Targeta AChBP 100 27.8 25.8 22
α 7h 28.8 93.7 44.9 40
α 7r 28.3 91.2 45.4 39.9
α 4h 24.9 45.9 97.6 53.4
β 2h 24.6 40.4 54.3 98.5
a Lower case letters c, r and h indicate chick, rat and human,
respectively
Fig. 1 Binding site region of the acetylcholine-binding protein
(AChBP) dimer model. N-2-Hydroxyethylpiperazine-N′-2-ethane-sul-
fonate (HEPES) from X-ray structure (colored by atom type; white
carbon atoms) and modeled acetylcholine (colored by atom type;
green carbon atoms) are displayed in ball and stick mode. Residues of
(+)-side and (−)-side are colored by atom type with the carbon atoms
in orange and magenta, respectively. All residues are displayed as
capped sticks and labeled
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subtypes of different species, confirming a common point
of origin during the evolution of the ligand-gated ionic
channel superfamily [37].
The AChBP homopentamer has five binding sites. Each
binding site is formed in a cleft made of different loops,
part of the principal subunit face (plus side), a series of β-
strands, and part of the complementary adjacent subunit
face (minus side) [9]. The plus/minus side interface is
formed by amino acids Tyr 89 (loop A), Trp 143, Thr 144,
His 145 (loop B), Tyr 185, double Cys 187,188 and
Tyr 192 (loop C), all belonging to the plus side, and the
minus side amino acids Trp 53, Gln 55 (β-strand D),
Leu 112, Met 114 (β-strand E). Within this interface, a
cavity with a top (Tyr 89, Tyr 185, Tyr 164, Trp 53), a
bottom (Leu 112) and walls (Tyr 192, Trp 143, the main
chain closed to His 145, the side chains of Met 114, Gln 55,
double Cys 187,188) is formed [9]. The aromatic residues
Tyr 89, Trp 143, Tyr 192 of the plus side and Trp 53 of the
minus side are involved in cation-π interactions with
HEPES and acetylcholine as shown in Fig. 1 [9]. At the
residue level, the homology of the four nicotinic models
with AChBP involves the plus side more than the minus
side, as shown in Table 2. The AChBP aromatic residues
Tyr 89, 192 and Trp 143 of the plus side, and Trp 53 of the
minus side are conserved and maintain a similar 3D-
orientation in all α and β subunits of different species
(Fig. 2). The residues Arg 104, Val 106, Leu 112, Met 114,
which form the minus side of AChBP, are poorly conserved
within the different nicotinic subunits (Table 2). In the
binding site region of the rat (α4)2(β2)3 model, the residues
expected to be involved in ligand binding are on the α
subunit Tyr 91 (loop A), Trp 147 (loop B), Tyr 188, double
Cys 190,191, Tyr 195 (loop C) and, on the β subunit,
Trp 55, Thr 57 (β-strand D), Val 109, Ser 111, Phe 117,
Leu 119 (β-strand E). The residues involved in binding are
highly conserved between the rat and human models. If we
compare the neuronal α4β2 and α7 subtypes of the same
species, high homology is present mostly between the α-
subunits (Tables 1, 2). Residues on the α-subunit (plus
side) are conserved within different subunits of the same
species and within the same subunit of different species,
confirming the findings of Le Novère et al. with the chick
(α7)5 model [29]. While the plus side is the principal
component involved in ligand binding in the interface of
adjacent subunits [1], the minus side behaves as the
complementary component and may be the side responsible
for subtype specificity. In fact, the complementary minus
side appears to be less conserved, and to have the capacity
Fig. 2 Superimposition of the binding site of AChBP (colored by
atom type; white carbon atoms), the rat (α4β2) pentamer model
(colored by atom type; orange carbon atoms), and the rat (α7)
pentamer model (colored by atom type; green carbon atoms). The
residues are labeled black (AChBP), red (α4β2) and blue (α7). In the
case of residue conservation within the three models, or within the rat
(α4β2) and (α7) models, only the AChBP amino acid side chain or
the AChBP and rat (α4β2)amino acid side chains are shown,
respectively. All side chains residues are displayed as capped sticks
Table 2 Residue homology between AChBP and the different nicotinic subtype models at the level of the 3D-structure. C Cys, F Phe, H His, L
Leu, M Met, Q Gln, S Ser, T Thr, V Val, Y Tyr, W Trp
Residue
Modela α-subunit β- or α-subunit (for α7)
AChBP Y89
a W143 T144 H145 Y185 C187 C188 Y192 W53 Q55 L112 M114
α4β2r Y91 W147 T148 Y149 Y188 C190 C191 Y195 W55 T57 F117 L119
α4β2h Y91 W147 T148 Y149 Y188 C190 C191 Y195 W55 T57 F117 L119
α7r Y91 W147 S148 Y149 Y186 C188 C189 Y193 W58 Q64 Q115 L117
α7h Y91 W147 S148 Y149 Y186 C188 C189 Y193 W58 Q64 Q115 L117
(+)-Side (−)-Side
a Residues are numbered based on the Swissprot sequences
a Lower case letters r and h indicate rat and human, respectively
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of adopting a number of different conformations. In
contrast, the plus side is fairly rigid, especially in the
bound-state conformation with the exception of some ring
flipping of the tyrosines [20].
In the α4β2 and α7 nicotinic models, the homologues of
the conserved aromatic residues Trp 143, Tyr 89, 185 and
192 (plus side) and Trp 53 (minus side) of AChBP form, on
different loops, a hydrophobic pocket in the inner part of
the cavity, which is amenable to cation-π interactions
(Fig. 1) [19]. On the other hand, the homologues of the
poorly conserved residues Gln 55, Leu 112 and Met 114
(minus side) of AChBP are on different β-sheets and cover
this aromatic pocket (Fig. 2). These residues are more
involved in hydrogen bonds between their main chain
amides and the ligand [20]. According to Henchman et al.
[19] hydrophobic interactions also contribute to the binding
of ACh to the minus side of the α7 nAChR subtype. The
ACh binding site is located at the interface between two
subunits, and the ligand must penetrate into a gorge to
interact specifically with the receptor and give the biolog-
ical response [19]. The double-cysteine loop seems to be
located, as in AChBP, at the entrance of the cavity
regulating access to the binding cavity [19–21].
Molecular dynamics
The AChBP pentamer and the AChBP dimer with
acetylcholine were submitted to the described minimization
and MD protocol. The RMSD of the AChBP pentamer and
dimer as a function of time clearly shows that a plateau,
representing stable conformation over time, was reached
already after 100 ps (Fig. 3). Moreover, comparison of the
structures at different times of MD with the starting
structure revealed no major changes in overall conforma-
tion. The low RMSD (1.5 Å) and structural comparison
along the simulation time indicates that, as expected, the
starting X-ray structure represents a stable conformation,
and that the MD protocol is well suited to assessing the
stability of the models.
The rat and human (α4)2(β2)3, and rat (α7)5 and human
(α7)2 models were submitted to the same MD protocol to
assess their stability. The RMSD graphics versus time are
shown in Fig. 3. The RMSD profile clearly shows that all
molecules reached a plateau and thus conformational
stability. As expected, the RMSD values of the nicotinic
models were found to be higher between 2.5 and 3 Å than
the values of the crystal structure AChBP.
The AChBP dimer complexed with acetylcholine was
investigated. The MD and the subsequent analysis of the
structure at different times revealed that the cation-π
interaction is stable over time. A low RMSD value of
around 1.3 Å was found, and conformational stability was
reached already after 50 ps. This is in agreement with the
importance of cation-π interactions in the binding of
ligands to nicotinic receptors, as shown by site-directed
mutagenesis of residues Tyr 93, Trp 149, Tyr 188, Tyr 195
and Trp 55 of the α7 nAChR subtype [36]. Point mutations
of these hydrophobic residues to alanine leads to dramat-
ically impaired binding properties of the agonists and
antagonists studied [38].
In the case of the AChBP dimer without acetylcholine,
Trp 143 (loop B) and Tyr 192 (loop C) shift toward the
inner of the cavity during MD, while in the AChBP dimer
with acetylcholine, Trp 143 and Tyr 192 do not show a
significant shift. Hence, this suggests that the observed shift
is due to the dynamic, although the movement of Trp 143
and Tyr 192 toward the inside of the binding cavity is
strictly dependent on the emptiness of the cavity itself. In
Fig. 3 Root-mean square devi-
ation (RMSD) graphics (all
atoms plotted) versus time
(picoseconds). The observed in-
crease in RMSD after 400 ps
with the human α7 dimer can be
expected due to the fragility of a
dimer model submitted to
lengthy dynamics
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fact, looking at the empty binding site region of rat and
human (α4)2(β2)3, rat (α7)5 and human (α7)2 models after
dynamics, we noted the same positional shift of the Trp and
Tyr residues—both conserved residues within the different
nicotinic α-subunits. A similar shift of Trp 148 in the
middle of the binding site was also observed by Henchman
et al. [19] during MD simulations of the α7 nAChR-LBD.
In the absence of the ligand, the binding site seems more
collapsed than when the ligand is bound, and this was well
quantified by following up the distance Cys 189–Leu 118
during the simulation period [19].
Lipophilicity and electropotential studies
Examination of the lipophilicity surface of AChBP and of
the rat and human α4β2 and α7 nicotinic models (Fig. 4)
revealed the polarity of the outer surface of the protein,
which is more exposed to the solvent, and the clear visible
hydrophobicity of the binding cavity. Inside the binding
cavity, the hydrophobic region involves primarily the
aromatic pocket composed of AChBP plus side residues
Trp 143, Tyr 89, 185 and 192 and the corresponding
residues (Table 2) in the α-subunit of the α4β2 and α7
nicotinic models. As shown in Fig. 4a and b, the
hydrophobic region of the rat α7 nicotinic model is larger
than that of the rat α4β2, involving a bigger portion of the
binding cavity surface. This would favor stronger inter-
actions between the binding site and the hydrophobic
moieties of ligands. The aromatic residues forming the
hydrophobic pocket establish cation-π interactions with the
positively charged nitrogen of the ligand [9, 39]. The minus
side of AChBP and the nicotinic models is less hydropho-
bic, suggesting the possibility of a different type of binding
to the ligand.
The lipophilicity surface of both human models is
similar to the rat models, revealing an outer hydrophilic
surface and an inner hydrophobic binding cavity. The
difference in lipophilicity between the α7 and α4β2
models (higher for the α7 model) is present in both rat
and human nicotinic subtypes (Fig. 4c,d). With the human
Fig. 4 Lipophilic surface of the
X-ray structure of the AChBP
dimer of the binding site cavity
of the rat α7 (a) and α4β2 (b),
and human α7 (c) and α4β2 (d)
nicotinic model performed with
the MOLCAD program. All
residues labeled are part of the
α7 (a,c) and α4 (b,d) subunit,
with the exception of Phe 117,
which is part of subunit β2 (d).
Brown Hydrophobic, grey slight
hydrophobic, green neutral, blue
hydrophilic
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models, we also confirmed that the plus side of the binding
site is more lipophilic than the minus side. This means that
the interpretation of the rat models can also be applied to
the human models. The plus side is involved in cation-π
interactions with the ligand [9, 19, 20, 38], while the minus
side, due to its lower hydrophobicity, may be involved in
another type of binding to the ligand. Moreover, the plus
side hydrophobic residues Trp 143, Tyr 185 and Tyr 192
are structurally part of loop C of the LBD, movement of
which upon binding of an agonist or antagonist is
connected with the opening (active state) or the closing
(inactive/resting state), respectively, of the ion channel pore
via TMD-M1 [18].
Investigation of the electrostatic potential of the binding
cavity of AChBP revealed a negatively charged surface
surrounding Trp 143, which attracts positively charged
ligands. Similar results were obtained with the rat α4β2
and α7 nicotinic models (Fig. 5a,b). The negatively
charged area surrounding Trp 147 is present in both models
but, in the rat α4β2 model, it is larger and involves also
Tyr 195 (Fig. 5a,b). In the rat α4β2 model, the distance
between Trp 147 and Tyr 195 is smaller (0.2–0.4 Å) than
the homologous residues in the rat α7 model. This means
that, of the two rat models, the α4β2 binding site region is
more capable of attracting and stabilizing positively
charged ligands deep inside the cavity. Another difference
between the two rat models is the role of α4β2-Lys 77 on
the β2-subunit. This residue showed a neutral electro-
static potential and a 3D location that would favor
interaction with hydrogen bonding acceptors of the
ligand, as we also observed in our docking studies with
the α4β2 nAChR subtype [39], whereas the homologous
residue Lys 72 in the α7 3D model is located further from
the binding cavity, making its involvement during ligand
binding less probable.
The electrostatic potential studies revealed that the
human α7 and α4β2 models are less negatively charged
in the binding site region (especially the minus side
electrostatic potential surface) than the rat models
(Fig. 5c,d). Moreover, the α7 residue Tyr 193 is involved
Fig. 5 Electrostatic surface po-
tential of the binding site cavity
of nAChR. Nicotinic models
performed with the MOLCAD
program: a rat α7, b rat α4β2, c
human α7, d human α4β2. All
residues labeled are part of the
α7 (a,c) or α4 (b,d) subunit
with the exception of Phe 117,
which belongs to subunit β2
(d). Violet Very negative, blue
negative, yellow neutral, red
very positive
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with less extension in the human than in the rat model. This
is due to the 3D-shift of the phenyl ring of Tyr towards
Trp 147, which causes less exposure of the phenyl
negatively charged surface of Tyr 193 in the binding cavity
(Fig. 5c). Instead, in the human α4β2 model, the 3D-
orientation of Trp 147 and Tyr 195 is similar to that of the
rat α4β2 model (the two residues are slightly closer in the
rat model) as shown in Fig. 5d.
A significant difference between the rat and human
α4β2 models is found by looking at the entrance to the
binding cavity. Due to the 3D orientation of Phe 117 in the
human model, the cavity entrance is shifted so that it differs
from that found in the rat model (Fig. 5d). Consequently, in
the α4β2 human model, the ligand will have to enter the
binding cavity in a different way than in the rat model.
While the kinetics of binding may be different because of
the peculiarity of the entrance, it is expected that the
binding orientation of acetylcholine in the binding site will
be similar because of the conservation of this major ligand-
receptor in both human models as well as the rat models.
This is due to the fact that the rat and human binding sites
of the same subtype share high similarities (>90%) at both
the level of subunit sequence (Table 2) and 3D binding
pocket structure. The differences between subtype binding
sites of the same species are important in investigating
subtype specificity, and in our case neuronal specificity,
because α7 and α4β2 are the subtypes most abundant in
the brain. The present lipophilic and electrostatic potential
surface analysis highlights a major feature: due to differ-
ences in the 3D orientation of the residues involved in
binding, the α4β2 binding site is less lipophilic and shows
a bigger negative potential area around Trp 147 than the α7
subtype. Similar data were obtained with both rat and
human models. Thus, this allows us to discriminate the two
binding sites and, as a consequence, suggests the possibility
of designing specific α4β2 nAChR subtype ligands.
Summary
The high homology between the different nicotinic subunits
from different species has allowed us to build models of the
extracellular domain of rat and human (α4)2(β2)3 and
(α7)5 nicotinic receptor subtypes, which are the most
abundant subtypes in the brain. These models were
successfully assessed using molecular dynamics and show
conformational stability over time.
Lipophilicity and electrostatic potential surface analyses
of the rat and human α4β2 and α7 nicotinic models
compared to AChBP revealed, for both species, the
importance of the hydrophobic aromatic pocket and the
critical role of the α-subunit Trp—the homologue of
AChBP Trp 143—for ligand binding. Moreover, due to
differences in the 3D orientation of the residues involved in
binding, the α4β2 binding site in both species shows minor
lipophilicity and a bigger negative potential area around
Trp 147 than the α7 subtype.
These models, which reveal differences between α7 and
α4β2 subtypes of the same species as well as the high
similarity between the same subtype of different species (rat
vs human in our case), will be useful as a valuable
framework for structure-based design of specific α4β2
nAChR subtype ligands aimed at improving human
therapeutic and diagnostic applications involving this
cationic channel receptor.
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